Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Top Forbes SHOOK advisors pledge $1.5M to fund kidney cancer treatment at Sloan Kettering Cancer Center in New York ...

Aurobindo Pharma's subsidiary, Eugia Pharma, gets USFDA nod for cancer drug Pazopanib. The drug treats renal cell carcinoma ...

SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Nicholas Kavoussi discussing artificial ...